Phase II
Calls for increased transparency in clinical trials have been growing and now many medical journals are requiring authors of submitted papers to disclose whether or not they will be sharing clinical trial results.
The drug showed what the company is calling a “substantial improvement in this symptom-driven score” at the 12-week point, but it did not differentiate from placebo.
Last week was busy for clinical trial news. Here’s a look.
ADC Therapeutics SA announced that the first patients have been dosed in a 100-patient pivotal Phase 2 clinical trial evaluating the efficacy and safety of ADCT-301 in patients with relapsed or refractory Hodgkin lymphoma The trial is intended to support the submission of a Biologics License Application to the U.S. Food and Drug Administration.
Findings further validate Cell Pouch and therapeutic cell performance in
MetrioPharm AG, a clinical stage biopharmaceutical company, reports positive results from its recently completed Phase II dose finding study of MP1032 in psoriasis patients.
Reata announced late Monday that the second part of its Phase II MOXIe trial met the goal of modified Friedreich’s Ataxia Rating Scale after 48 weeks of treatment.
MGB Biopharma, a biopharmaceutical company developing a novel class of anti-infectives to address the major global problem of antibiotic resistance, announces an update on progress in its Phase IIa clinical study.
With No Safety Concerns, DSMB Recommends Trial Continues; Dose Increase Planned
Faron Pharmaceuticals Oy announces feedback from the MATINS study data monitoring committee from the ongoing dose escalation study from part I of the MATINS trial.
PRESS RELEASES